NEWS | BEAM Alliance


Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference

Allschwil, Switzerland, June 7, 2019

Polyphor AG (SIX: POLN) presented yesterday new data from pulmonary delivery of its lead antibacterial candidate of the novel Outer Membrane Protein Targeting Antibiotic (OMPTA) class, murepavadin, at the 42nd European Cystic Fibrosis Conference in Liverpool, United Kingdom.

The results from an in vivo study, which investigated the pharmacokinetics, tolerability and efficacy of murepavadin in neutropenic mouse lung infection models against Pseudomonas aeruginosa (PA), demonstrated linear, dose proportional, pharmacokinetics when administered by intratracheal application. Exposure of the epithelial lining fluid to murepavadin was favorable compared to that in plasma. Murepavadin displayed potent activity toward PA infections when delivered intratracheally. Initial experiments further suggest that murepavadin was well tolerated when administered by inhalation route.

Full PR available here